JP2025041725A5 - - Google Patents
Info
- Publication number
- JP2025041725A5 JP2025041725A5 JP2024221344A JP2024221344A JP2025041725A5 JP 2025041725 A5 JP2025041725 A5 JP 2025041725A5 JP 2024221344 A JP2024221344 A JP 2024221344A JP 2024221344 A JP2024221344 A JP 2024221344A JP 2025041725 A5 JP2025041725 A5 JP 2025041725A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- pharmaceutical composition
- seq
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018231948 | 2018-12-11 | ||
| JP2018231948 | 2018-12-11 | ||
| JP2020560106A JP7608164B2 (ja) | 2018-12-11 | 2019-12-10 | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ |
| PCT/JP2019/048171 WO2020122034A1 (ja) | 2018-12-11 | 2019-12-10 | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560106A Division JP7608164B2 (ja) | 2018-12-11 | 2019-12-10 | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025041725A JP2025041725A (ja) | 2025-03-26 |
| JP2025041725A5 true JP2025041725A5 (https=) | 2025-10-08 |
Family
ID=71076370
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560106A Active JP7608164B2 (ja) | 2018-12-11 | 2019-12-10 | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ |
| JP2024221344A Pending JP2025041725A (ja) | 2018-12-11 | 2024-12-18 | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560106A Active JP7608164B2 (ja) | 2018-12-11 | 2019-12-10 | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220023436A1 (https=) |
| EP (1) | EP3909580A4 (https=) |
| JP (2) | JP7608164B2 (https=) |
| KR (1) | KR102905497B1 (https=) |
| CN (1) | CN113271942A (https=) |
| AU (1) | AU2019396895B2 (https=) |
| BR (1) | BR112021011119A2 (https=) |
| EA (1) | EA202191641A1 (https=) |
| SG (1) | SG11202106248XA (https=) |
| TW (1) | TW202034959A (https=) |
| WO (1) | WO2020122034A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102905497B1 (ko) * | 2018-12-11 | 2025-12-30 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 컨쥬게이트와 parp 저해제의 조합 |
| IL288485B2 (en) * | 2019-05-29 | 2026-04-01 | Daiichi Sankyo Co Ltd | Anti-TROP2 antibody conjugates - a drug for use in cancer treatment |
| JP2023545096A (ja) * | 2020-10-09 | 2023-10-26 | アストラゼネカ ユーケー リミテッド | 抗体－薬物コンジュゲート及びｐａｒｐ１選択的阻害薬の組み合わせ |
| WO2022248268A1 (en) * | 2021-05-28 | 2022-12-01 | Adc Therapeutics Sa | Combination therapy |
| TW202320858A (zh) | 2021-07-19 | 2023-06-01 | 美商薩諾管理公司 | 免疫接合物及方法 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| AU2022392822A1 (en) | 2021-11-18 | 2024-05-02 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and parp1 selective inhibitor |
| CN116407612A (zh) * | 2021-12-29 | 2023-07-11 | 上海市第十人民医院 | 一种药物组合物及其在制备抗肿瘤药物中的应用 |
| CN119317447A (zh) * | 2022-04-12 | 2025-01-14 | 米纳瓦生物技术公司 | 抗可变muc1*抗体及其用途 |
| CN119255825A (zh) * | 2022-05-24 | 2025-01-03 | 第一三共株式会社 | 抗-cdh6抗体-药物缀合物的剂量方案 |
| WO2024190815A1 (ja) * | 2023-03-14 | 2024-09-19 | 第一三共株式会社 | 抗ｃｄｈ６抗体－薬物コンジュゲートとｖｅｇｆ阻害剤の組み合わせ |
| AU2024248799A1 (en) * | 2023-03-31 | 2025-10-23 | Daiichi Sankyo Company, Limited | Combination of anti-CDH6 antibody-drug conjugate and HIF-2alpha inhibitor |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| EP4495003A1 (en) | 2023-07-20 | 2025-01-22 | AIRBUS HELICOPTERS DEUTSCHLAND GmbH | An external cargo adapter for use with a rotorcraft |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026019375A1 (en) * | 2024-07-19 | 2026-01-22 | Hummingbird Bioscience Pte. Ltd. | B7h3-binding molecules |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| CN100340575C (zh) | 1999-06-25 | 2007-10-03 | 杰南技术公司 | 人源化抗ErbB2抗体及其在制备药物中的应用 |
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| WO2007133855A2 (en) | 2006-03-27 | 2007-11-22 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| KR101598229B1 (ko) | 2007-02-16 | 2016-02-26 | 메리맥 파마슈티컬즈, 인크. | Ｅｒｂｂ3에 대한 항체 및 이의 용도 |
| IN2014DN06806A (https=) | 2012-02-10 | 2015-05-22 | Univ Maryland | |
| ES2773710T3 (es) * | 2012-10-11 | 2020-07-14 | Daiichi Sankyo Co Ltd | Enlazadores para conjugados de anticuerpo - fármaco |
| WO2014061277A1 (ja) | 2012-10-19 | 2014-04-24 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート |
| AU2014371934B2 (en) | 2013-12-25 | 2020-01-23 | Daiichi Sankyo Company, Limited | Anti-TROP2 antibody-drug conjugate |
| IL310627B2 (en) * | 2014-01-31 | 2026-04-01 | Daiichi Sankyo Co Ltd | Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof |
| JP2017114763A (ja) | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗ｃｄ９８抗体−薬物コンジュゲート |
| KR102445502B1 (ko) | 2014-04-10 | 2022-09-21 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
| EP3130608B1 (en) | 2014-04-10 | 2019-09-04 | Daiichi Sankyo Co., Ltd. | (anti-her2 antibody)-drug conjugate |
| US10195175B2 (en) * | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
| CN116059395A (zh) | 2015-06-29 | 2023-05-05 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| JP6679762B2 (ja) | 2017-01-17 | 2020-04-15 | 第一三共株式会社 | 抗ｇｐｒ２０抗体及び抗ｇｐｒ２０抗体−薬物コンジュゲート |
| TW202532104A (zh) * | 2017-05-15 | 2025-08-16 | 日商第一三共股份有限公司 | 抗體－藥物結合物及其用途 |
| IL324591A (en) | 2017-08-31 | 2026-01-01 | Daiichi Sankyo Co Ltd | Improved antibody-drug conjugate production methods |
| KR102905497B1 (ko) * | 2018-12-11 | 2025-12-30 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 컨쥬게이트와 parp 저해제의 조합 |
-
2019
- 2019-12-10 KR KR1020217021368A patent/KR102905497B1/ko active Active
- 2019-12-10 US US17/312,084 patent/US20220023436A1/en active Pending
- 2019-12-10 EA EA202191641A patent/EA202191641A1/ru unknown
- 2019-12-10 SG SG11202106248XA patent/SG11202106248XA/en unknown
- 2019-12-10 EP EP19895941.3A patent/EP3909580A4/en active Pending
- 2019-12-10 AU AU2019396895A patent/AU2019396895B2/en active Active
- 2019-12-10 CN CN201980082698.7A patent/CN113271942A/zh active Pending
- 2019-12-10 WO PCT/JP2019/048171 patent/WO2020122034A1/ja not_active Ceased
- 2019-12-10 TW TW108145171A patent/TW202034959A/zh unknown
- 2019-12-10 JP JP2020560106A patent/JP7608164B2/ja active Active
- 2019-12-10 BR BR112021011119A patent/BR112021011119A2/pt unknown
-
2024
- 2024-12-18 JP JP2024221344A patent/JP2025041725A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025041725A5 (https=) | ||
| JPWO2020122034A5 (https=) | ||
| JP2023539715A5 (https=) | ||
| JP2023545096A5 (https=) | ||
| JP7608164B2 (ja) | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ | |
| JP2023070678A5 (https=) | ||
| JPWO2020031936A5 (https=) | ||
| TWI865337B (zh) | 抗體-藥物結合物之有效的製造方法 | |
| JP2020515578A5 (https=) | ||
| JPWO2020130125A5 (https=) | ||
| JP2022095908A5 (https=) | ||
| JP2020019787A5 (https=) | ||
| JP2024075668A (ja) | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ | |
| JP2019031565A5 (https=) | ||
| JP2023531252A5 (https=) | ||
| JPWO2022102695A5 (https=) | ||
| CA3047359A1 (en) | Hdac inhibitors-based antibody drug conjugates (adcs) and use in therapy | |
| JP2010535713A5 (https=) | ||
| JP2024546605A5 (https=) | ||
| JP2024501894A5 (https=) | ||
| JP2020500834A5 (https=) | ||
| JPWO2019230645A5 (https=) | ||
| JPWO2022102634A5 (https=) | ||
| JP2011505371A5 (https=) | ||
| JP2025509266A5 (https=) |